Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Imatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 20/20 | 0.98 |
| ▸ | BCR known ✓ | P11274 | 14/20 | 0.98 |
| ▸ | KIT known ✓ | P10721 | 12/20 | 0.98 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.98 |
| ▸ | ABL2 | P42684 | 7/20 | 0.98 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.98 |
| ▸ | LYN | P07948 | 3/20 | 0.98 |
| ▸ | SRC | P12931 | 2/20 | 0.98 |
| ▸ | SYK | P43405 | 2/20 | 0.98 |
| ▸ | PLK4 | O00444 | 1/20 | 0.98 |
| ▸ | DDX3X | O00571 | 1/20 | 0.98 |
| ▸ | GAK | O14976 | 1/20 | 0.98 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.98 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.98 |
| ▸ | CA12 | O43570 | 1/20 | 0.98 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | EGFR | P00533 | 1/20 | 0.98 |
| ▸ | CA1 | P00915 | 1/20 | 0.98 |
| ▸ | CA2 | P00918 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imatinib SCHEMBL2929858 | 1.00 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL1977949 | 1.00 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL662077 | 0.99 | ABL1 (0.97) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL2236091 | 0.99 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL29351601 | 0.99 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL29355523 | 0.99 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL3827 | 0.99 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL15201213 | 0.98 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL3138052 | 0.98 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL1462774 | 0.98 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119546336-A | Allo-low immunity bionic nano vesicle for treating cancer | T·马尔科姆 | 2025-02-28 | — | — | CN | claimed |
| CN-112370529-A | Compound preparation for treating pulmonary hypertension and preparation method thereof | 中国药科大学 | 2021-02-19 | — | — | CN | claimed |
| EP-2608791-B1 | A PROCESS FOR THE PREPARATION OF IMATINIB BASE | MUSTAFA NEVZAT ILAC SANAYII A S (TR) | 2016-05-18 | — | — | EP | claimed |
| EP-2608791-A1 | A PROCESS FOR THE PREPARATION OF IMATINIB BASE | Mustafa Nevzat Ilac Sanayii A.S. (TR) | 2013-07-03 | — | — | EP | claimed |
| US-8252926-B2 | Process for the preparation of imatinib base | Mustafa Nevzat llaç Sanayii A.S. (TR) | 2012-08-28 | — | — | US | claimed |
| WO-2012026897-A1 | A PROCESS FOR THE PREPARATION OF IMATINIB BASE | MUSTAFA NEVZAT iLAÇ SANAYU A.Ş. (TR) | 2012-03-01 | — | — | WO | claimed |
| US-20120046463-A1 | Process for the Preparation of Imatinib Base | MUSTAFA NEVZAT ILAC SANAYII A.S. (TR) | 2012-02-23 | — | — | US | claimed |
| CN-102040587-A | Preparation method of imatinib mesylate | NANYIN HAN | 2011-05-04 | — | — | CN | claimed |
| CN-116406355-B | P38 alpha mitogen-activated protein kinase inhibitors | GEN1E生命科学公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20250127716-A1 | INHALED IMATINIB FOR TREATMENT OF PULMONARY HYPERTENSION | JUSTUS-LIEBIG-UNIVERSITAET GIESSEN (DE) | 2025-04-24 | — | — | US | disclosed |
| US-20250090463-A1 | INHALED IMATINIB FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | AVALYN PHARMA INC. | 2025-03-20 | — | — | US | disclosed |
| CN-119546336-A | Allo-low immunity bionic nano vesicle for treating cancer | T·马尔科姆 | 2025-02-28 | — | — | CN | disclosed |
| CN-119242639-A | Aptamer specifically binding to imatinib and screening and application thereof | 福州大学 | 2025-01-03 | — | — | CN | disclosed |
| EP-4472609-A1 | INHALED IMATINIB FOR TREATMENT OF PULMONARY HYPERTENSION | Justus-Liebig-Universität Gießen (DE) | 2024-12-11 | — | — | EP | disclosed |
| EP-1988089-A1 | Imatinib base, and imatinib mesylate and processes for preparation thereof | Sicor, Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20080207904-A1 | Imatinib base, and imatinib mesylate and processes for preparation thereof | SICOR INC. | 2008-08-28 | — | — | US | disclosed |
| WO-2008057291-A2 | CRYSTALLINE AND AMORPHOUS IMATINIB BASE, IMATINIB MESYLATE- AND PROCESSES FOR PREPARATION THEREOF | SICOR INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| US-20060173182-A1 | Process of preparing imatinib and imatinib prepared thereby | CIPLA LIMITED (IN) | 2006-08-03 | — | — | US | disclosed |
| EP-1599462-A2 | PROCESS OF PREPARING IMATINIB | Cipla Ltd. (IN) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004074502-A2 | A PROCESS OF PREPARING IMATINIB | CIPLA LTD (IN) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250090463-A1 | INHALED IMATINIB FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | ALK, JAK1, PAH | ABL1 4/4885BCR 353/4885KIT 204/4885 |
| US-20060173182-A1 | Process of preparing imatinib and imatinib prepared thereby | ABL1, ABL2, MET | ABL1 1/4885BCR 38/4885KIT 13/4885 |
| US-20080207904-A1 | Imatinib base, and imatinib mesylate and processes for preparation thereof | ABL1, ABL2, MET | ABL1 1/4885BCR 24/4885KIT 5/4885 |
| US-20120046463-A1 | Process for the Preparation of Imatinib Base | ABL1, ABL2, ALK | ABL1 1/4885BCR 12/4885KIT 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.